BRANDI GILMORE: Open Payments
NPI 1164627824 · RACELAND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$357 in 17 payments from 8 companies in 2025. Trend: 2023 $674 · 2024 $410 · 2025 $357
Food & beverage: $357
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $91 |
| Merck Sharp & Dohme LLC | 3 | $74 |
| ABBVIE INC. | 3 | $61 |
| ViiV Healthcare Company | 2 | $47 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Gilead Sciences, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
Products named: CAPLYTA, PIFELTRO, VRAYLAR, APRETUDE, SPRAVATO, Dexcom G6 Transmitter, Yeztugo, REXULTI.
Industry payments across LA — which companies pay providers there.
